Key facts
- This page summarizes Eric D. Shaff's Form 4 filing for Sigilon Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Jun 2021, 07:15.
Eric D. Shaff - 24 Jun 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 24 Jun 2021
- Net transaction value
- +$88,613
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2021, 07:15:17 UTC
- Next SEC filing
- 08 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Kowalsky, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric D. Shaff filed Form 4 for Sigilon Therapeutics, Inc. on 28 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$88,613.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SGTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $88,613
- Shares
- +8,888
- Change %
- Price
- $9.97*
- Shares after
- 8,888
- Date
- 24 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,888
- Exercise price
- $9.97
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022.